OSE Immunotherapeutics Halts Two Programs to Focus on Tedopi®

Strategic Realignment and Resource Concentration

OSE Immunotherapeutics is undergoing a targeted realignment of its R&D portfolio by pausing the development of OSE-230, allowing a focus of resources on lusvertikimab (OSE-127) and Tedopi®. These two products are expected to achieve several clinical milestones over the next three years. For lusvertikimab, the company has selected chronic pouchitis and hidradenitis suppurativa as potential next target indications, based on a biological rationale linked to the IL-7 receptor. Concurrently, a subcutaneous formulation is being developed to advance lusvertikimab in ulcerative colitis, while the Phase 3 study of Tedopi® in non-small cell lung cancer continues.

Decisions on Program Pauses and Terminations

The decision to pause OSE-230 stems from an amendment to the collaboration agreement signed in December 2025 and reflects the company's intent to advance its most mature clinical programs, which are likely to create short-term value. OSE will also terminate exploratory research activities related to the CLEC-1 program in oncology, an early myeloid target developed at the preclinical stage that does not align with the company’s immediate clinical priorities. Meanwhile, Boehringer Ingelheim has decided to halt the development of BI 770371 in NASH after a Phase 2 exploratory study did not demonstrate sufficient efficacy in this indication. This specific decision regarding NASH does not affect the development in oncology of the molecule, where several Phase 1 studies continue as planned. The company continues to actively evaluate its financing options to support the progression of its advanced-stage clinical portfolio.